High prevalence of the 999del5 mutation in icelandic breast and ovarian cancer patients

To access publisher full text version of this article. Please click on the hyperlink in Additional Links field Studies on Icelandic breast cancer families have shown that most of them segregate a 999del5 BRCA2 mutation. Here, we report the frequency of the 999del5 BRCA2 mutation in an Icelandic cont...

Full description

Bibliographic Details
Main Authors: Johannesdottir, G, Gudmundsson, J, Bergthorsson, J T, Arason, A, Agnarsson, B A, Eiriksdottir, G, Johannsson, O T, Borg, A, Ingvarsson, S, Easton, D F, Egilsson, V, Barkardottir, R B
Other Authors: Department of Pathology, University Hospital of Iceland, Reykjavik, Iceland.
Format: Article in Journal/Newspaper
Language:English
Published: Waverly Press 2010
Subjects:
Adult
Age Factors
Aged
80 and over
BRCA2 Protein
Base Sequence
Breast Neoplasms
Female
Gene Deletion
Humans
Middle Aged
Molecular Sequence Data
Neoplasm Proteins
Ovarian Neoplasms
Transcription Factors
Iceland
Online Access:http://hdl.handle.net/2336/112033
Description
Summary:To access publisher full text version of this article. Please click on the hyperlink in Additional Links field Studies on Icelandic breast cancer families have shown that most of them segregate a 999del5 BRCA2 mutation. Here, we report the frequency of the 999del5 BRCA2 mutation in an Icelandic control population and four different groups of cancer patients diagnosed with (a) breast cancer; (b) ovarian cancer; (c) prostate cancer (patients younger than 65 years); and (d) other cancer types. The proportions of individuals carrying the mutation were 0.4% in the control population and in the patient groups 8.5%, 7.9%, 2.7%, and 1.0%, respectively. Our results indicate that BRCA2 confers a very high risk of breast cancer and is responsible for a substantial fraction of breast and ovarian cancer in Iceland, but only a small proportion of other cancers.

Similar Items